Publication

No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting

Darlene Goldstein
2011
Journal paper

Abstract

Objective. About 70% of epithelial ovarian cancer patients (EOC) are diagnosed at advanced stage with a five-year survival rate of only 30%. Whilst CA125 detects peritoneally-spread disease, it has limited sensitivity for early cancers, many of which are potentially curable.

Official source

https://infoscience.epfl.ch/record/171353?ln=en

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Graph Chatbot

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting

Graph Chatbot

Chat with Graph Search

An autonomous microfluidic device for identification and analysis of individual clinically-relevant mammalian cells

Bioengineering Methods to Improve in vitro Adoptive Cell Therapy based on Tumor-Infiltrating Lymphocytes

An autonomous microfluidic device for identification and analysis of individual clinically-relevant mammalian cells

Bioengineering Methods to Improve in vitro Adoptive Cell Therapy based on Tumor-Infiltrating Lymphocytes